The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Upon completion of the activity, participants should be able to:

• Analyze recent trends regarding hypothyroid management in the United States, use of statins in conjunction with IV glucocorticoids in the treatment of Graves eye disease and recent data informing management for the thyroid cancer risk spectrum
• Interpret serum T3 and serum T4 levels on LT4-treated patients and current approaches to LT3 and use in treatment of hypothyroidism
• Review strengths and weaknesses of using different classes of Thyroglobulin (Tg) method to monitor Differentiated Thyroid Cancer (DTC) patients amd Diagnose and manage checkpoint inhibitors-induced thyroid dysfunction
• Describe how the latest therapeutic considerations are shaping the new treatment paradigm of hyperthyroidism during pregnancy
• Describe FDA approved and investigational targeted therapies for thyroid cancer in the context of clinical trials

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

• Benjamin Gigliotti, MD - Assistant Professor of Medicine University of Rochester: Blueprint Medicines (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- RET+ Virtual Thyroid Discussion Forum (a 7-hour advisory board commitment), started 3/3/21, ended 3/17/21)
  
• Alex Tessnow, MD - Associate Professor University of Texas Southwestern Medical Center: Horizon (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Spectrix Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing).
  
• Antonio C Bianco, MD, PhD - Professor of Medicine University of Chicago: Abbott/AbbVie (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Allergan (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Synthonic (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Giuseppe Barbesino, MD - Assistant Professor Massachusetts General Hospital/Harvard Medical School: Horizon Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Anupam Kotwal, MD - Assistant Professor University of Nebraska Medical Center: Horizon Therapeutics, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing).
  
• Maria E Cabanillas, MD, FACE - Professor The University of Texas MD Anderson Cancer Center: Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eisai (Self) : Research Grant (Status: Terminated --- 11/15/2019); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Exelixis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Genentech (Self) : Research Grant (Status: Ongoing); LOXO (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Merck (Self) : Research Grant (Status: Ongoing)
  
• Mimi Hu, MD - Professor The University of Texas MD Anderson Cancer Center: Eli Lilly (Self) : Contracted Research (Status: Ongoing)

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

• Benjamin J. Gigliotti, MD
• Alex Tessnow, MD
• Antonio C. Bianco, MD, PhD
• Carole Spencer, PhD
• Anupam Kotwal, MD
• Giuseppe Barbesino, MD
• Chrysoula Dosiou, MD, MS